Clinical trial NCT00054132: Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Official title: A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Recurrent Breast Carcinoma
Stage IV Breast Cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2003-02-06
Enrollment: 38
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies how well erlotinib hydrochloride and bevacizumab work in treating patients with stage IV breast cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving erlotinib hydrochloride and bevacizumab may be an effective treatment for breast cancer.

Detailed description: PRIMARY OBJECTIVES:

I. To determine the efficacy of bevacizumab in combination with OSI-774 (erlotinib hydrochloride) in patients with previously treated metastatic breast cancer, as measured by objective response rate.

SECONDARY OBJECTIVES:

I. To determine the toxicity of bevacizumab in combination with OSI-774 in patients with previously treated metastatic breast cancer.

II. To evaluate the efficacy of bevacizumab in combination with OSI-774 in patients with previously treated metastatic breast cancer, as measured by time to disease progression, duration of response and the proportion of patients with stabilization of disease \>= 6 months.

III. To determine the molecular profile of the patient's primary breast tumor, and to explore the relationship between these molecular characteristics and the response to treatment.

IV. To explore changes in biological markers in pre- and post-treatment tumor tissue in a subset of patients with accessible sites of disease.

V. To explore a pre- and post-treatment analysis of circulating endothelial cells and the relationship of this analysis to serum markers of angiogenesis as well as response to treatment.

VI. To obtain serial measurements of circulating epithelial cells and explore the relationship of these cells with circulating endothelial cells, markers of angiogenesis, and epidermal growth factor receptor (EGFR) expression.

OUTLINE:

Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-21 and bevacizumab intravenously (IV) over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Eligibility criteria: Inclusion Criteria:

* Patients must have histologically or cytologically confirmed carcinoma of the breast with metastatic (stage IV) disease that is currently stable or progressing after therapy
* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques or as \>= 10 mm with spiral computed tomography (CT) scan
* Patients must have either stable disease or disease progression on or after therapy with one or two conventional chemotherapy regimens for the treatment of metastatic (stage IV) breast cancer

  * Prior treatment with high-dose chemotherapy and autologous stem cell/bone marrow transplantation is allowed, and is considered one prior regimen when administered for metastatic disease
  * There is no restriction for the number of prior hormonal therapies or immunotherapies
  * If human epidermal growth factor receptor 2 (Her2)/neu-positive (defined as 3+ by immunohistochemistry \[IHC\] or positive by fluorescence in situ hybridization \[FISH\]), prior therapy with trastuzumab required
  * Any number of prior regimens of chemotherapy and/or hormonal therapy are allowed in the adjuvant setting, and do not count towards prior therapy when determining eligibility for this trial
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)
* Life expectancy of greater than 3 months
* Leukocytes \>= 3,000/ul
* Absolute neutrophil count \>= 1,000/ul
* Platelets \>= 75,000/ul
* Total bilirubin within normal institutional limits
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\[) =\< 2.5 X institutional upper limit of normal
* Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min for patients with creatinine levels outside institutional normal using the Cockcroft-Gault formula
* Women of childbearing potential must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
* Patients must have breast cancer tissue available as either paraffin blocks or unstained slides for planned correlative science sub study
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients who have had chemotherapy, radiotherapy immunotherapy or investigational therapy within 3 weeks prior to starting treatment (6 weeks for nitrosoureas or mitomycin C), or hormonal therapy within 2 weeks prior to starting treatment
* Patients may not be receiving any other investigational agents
* History or evidence upon physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke); all subjects must have a baseline CT or magnetic resonance imaging (MRI) of the head
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to OSI-774 or bevacizumab
* Prior treatment with kinase insert domain receptor (KDR) inhibitors (e.g. vascular endothelial growth factor \[VEGF\] Trap, Su5416, Su6668, ZD6474, PTK757, IMC-1CII)
* Prior treatment with EGFR targeting therapies (e.g. ZD1839 or C225)
* Major surgery, open biopsy or significant traumatic injury occurring within 28 days prior to treatment; this does not apply to indwelling catheters, which require an interval of at least 24 hours between placement of the catheter and treatment with bevacizumab
* Current or recent (within 10 days prior to treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters; for subjects receiving warfarin, international normalized ratio \[INR\] should be \< 1.5)
* Chronic daily treatment with aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit the platelet function (e.g. cyclooxygenase \[COX\]-1 inhibitors)
* Presence of bleeding diathesis or coagulopathy
* Cumulative anthracycline and anthracenedione exposure as follows: doxorubicin \> 450 mg/m\^2; epirubicin \> 700 mg/m\^2; liposomal doxorubicin \> 550 mg/m\^2; mitoxantrone \> 140 mg/m\^2
* Proteinuria at baseline; subjects unexpectedly discovered to have \>= 1+ proteinuria should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate =\< 500 mg protein/ 24 hours to allow participation in the study
* Cardiac ejection fraction (multigated acquisition scan \[MUGA\] or echocardiogram) less than the local institution lower limit of normal
* Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjögren's syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test)
* Serious, non-healing wound, ulcer, or bone fracture
* Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or grade II or greater peripheral vascular disease within 1 year prior to day 0
* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or prior surgical procedures affecting absorption
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with OSI-774
* Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
* Patients with recent (within 6 months) arterial thrombotic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, myocardial infarction (MI), or clinically significant peripheral artery disease

Primary outcomes:
measure: Level of EGFR Expression
timeFrame: Up to 12 years
measure: Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors
timeFrame: Up to 12 years
Secondary outcomes:
measure: Duration of Response
timeFrame: From the time measurement criteria are met for CR and PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years
measure: Time to Progression
timeFrame: From the start of treatment until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years
measure: Number of Patients Evaluated for Toxicity
timeFrame: up to 12 years
measure: Participants With Duration of Stable Disease Greater Than or Equal to 6 Months
timeFrame: From the start of treatment until the first date that recurrent or progressive disease is objectively documented, assessed up to 12 years
Other outcomes:
measure: HER2 Status
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for EGFR
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for Human Epidermal Growth Factor Receptor 3 (HER3)
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for Marker of Proliferation Ki-67 (Ki-67)
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for p27
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for Phosphorylated-mitogen-activated Protein Kinase (MAP) Kinase
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for Phosphorylated-v-akt Murine Thymoma Viral Oncogene Homolog 1 (Akt)
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for Tumor Protein p53 (p53)
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for VEGF
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for VEGF Receptor (VEGFR)-1
timeFrame: Up to 12 years
measure: Percentage of Cells Staining Positive for VEGFR-2
timeFrame: Up to 12 years
Locations:
city: San Francisco
country: United States
facility: UCSF Medical Center-Mount Zion
state: California
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Maura Dickler
role: PRINCIPAL_INVESTIGATOR
References: